• Explore /
  • Poster
  • / A phase I/II first-in-human study of a novel anti-MAGE-A4 TCR/anti-CD3 bispecific (IMC-C103C) as monotherapy and in combination with atezolizumab in HLA-A*02:01-positive patients with MAGE-A4-positive advanced solid tumors (IMC-C103C-101).

A phase I/II first-in-human study of a novel anti-MAGE-A4 TCR/anti-CD3 bispecific (IMC-C103C) as monotherapy and in combination with atezolizumab in HLA-A*02:01-positive patients with MAGE-A4-positive advanced solid tumors (IMC-C103C-101).

Abstract Poster

Authors

null

George R. Blumenschein, Jr.

Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

George R. Blumenschein, Jr. , Diwakar Davar , Rodolfo Gutierrez , Neil Howard Segal , Melissa Lynne Johnson , Mohammed M. Dar , Shannon Marshall

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

New Targets and New Technologies (IO)

Clinical Trial Registration Number

NCT03973333

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS3165)

DOI

10.1200/JCO.2020.38.15_suppl.TPS3165

Abstract #

TPS3165

Poster Bd #

229

Abstract Disclosures

Similar Posters

First Author: Jiaxin Niu

First Author: John D. Powderly

First Author: Omar Saavedra Santa Gadea

First Author: Kyriakos P. Papadopoulos